Lamivudine therapy for Korean children with chronic hepatitis B

Yonsei Medical Journal

Volumn 48, Issue 6, 2007, Pages 927-933

  Koh, Hong ^a   Baek, Seoung Yon ^a   Chung, Ki Sup ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Children; Chronic hepatitis B; HBeAg; HBV DNA; Lamivudine; Pre treatment ALT

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CHRONIC HEPATITIS; DRUG EFFICACY; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KAPLAN MEIER METHOD; KOREA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROPORTIONAL HAZARDS MODEL; RECURRENCE RISK; SEROCONVERSION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS MUTATION;

ADOLESCENT; ADULT; AGE FACTORS; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; COHORT STUDIES; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KOREA; LAMIVUDINE; MALE; SEX FACTORS; TREATMENT OUTCOME;

EID: 38049136727     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2007.48.6.927     Document Type: Article

References (21)

1. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effecton hepatitis B eantigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001;34:139-45.
2. Choi HJ, Kim YS, Park KS, Lee SI, Moon YM, Kang JK, et al. Clinical study on distribution of hepatitis B virus markers in Korea population. Korean J Gastroenterol 1983;15:163-71.
3. Jeong IS, Chung KS. The therapeutic effect of interferon-alpha treatment in children with chronic hepatitis B. Korean J Pediatr 1997;40:955-64.
4. Chang JY, Jeong SJ, Kim SK, Son BK, Hong YJ, Hong KS. Positive rate of HBsAg in school children in Incheon area. Korean J Pediatr Infect Dis 2003;10:153-8.
5. Mansour TS, Jin H, Wang W, Hooker EU, Ashman C, Cammack N, et al. Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enatiomers of 2′-deoxy-3′-oxa-4′-thiocytidine and their 5-fiuoro analogues in vitro. J Med Chem 1995;38:1-4.
6. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai AI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.
7. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997;26:1393-5.
8. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711-6.
9. Allen MI, Gauthier J, DesLauriers M, Bourne EJ, Carrick KM, Baldanti F, et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced usceptibility to lamivudine. J Clin Microbiol 1999;37:3338-47.
10. Cha CH, Sohn YH, Jang SS, Lee HJ, Lee KJ, Shin ES, et al. Genotype analysis of hepatitis B virus isolated from Korean hepatitis patients. Korean J Lab Med 2003; 23:352-6.
11. Chung JY, Han TH, Hwang ES, Ko JS, Seo JK. Prevalence and genotype of transfusion-transmitted virus in children with hepatitis and normal control. Korean J Pediatr Gastroenterol Nutr 2005;8:202-12.
12. Bae SH, Yoon SK, Jang JW, Kim CW, Nam SW, Choi JY, et al. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci 2005;20:816-20.
13. Kim JH, Koh DK, Hur JK, Kang JH, Nainan OV, Margolis HS. The incidence rate of hepatitis B virus surface gene variants in Korean children with immunoprophylaxis failure of perinatal infection. Korean J Hepatol 2005;11:320-8.
14. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine is initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
15. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-8.
16. Sokal EM, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006;43:225-32.
17. Jonas MM, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13.
18. Ozgenq F, Arikan C, Sertoz RY, Nart D, Aydogdu S, Yagci RY. Effect of long-term lamivudine in chronic hepatitis B virus-infected children. Antivir Ther 2004; 9:729-32.
19. Liberek A, Szaflarska-Poplawska A, Korzon M, Luczak G, Góra-Gebka M, Loś-Rycharska E, et al. Lamivudine therapy for children with chronic hepatitis B. World J Gastroenterol 2006;12:2412-6.
20. Alexander G, Baba CS, Chetri K, Negi TS, Ghoudhuri G. High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with lamivudine: results of an open labeled trial. BMC Gastroenterol 2005;5:29.
21. Hartman C, Berkowitz D, Shouval D, Eshach-Adiv O, Hino B, Rimon N, et al. Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon. Pediatr Infect Dis J 2003;22:224-9.